Ctrl K
Last 33 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -16.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 185.78 | 2.75 | 10.97 | 7.99 | 3.17 | 1.54 | 2.30 | 2.77 | 1.10 | 1.46 | 0.94 | 0.85 | 0.62 | 0.88 | 0.64 | 0.54 | 0.47 | 0.50 | 0.54 | 0.76 | 0.97 |
| — | +78.6% | +376.7% | +188.7% | +187.8% | +5.4% | +144.1% | +227.3% | +77.8% | +66.1% | +46.5% | +56.3% | +31.2% | +75.1% | +19.7% | -28.8% | -51.0% | -94.5% | -93.5% | -90.4% | -92.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -122.3% | -20.7% | -42.9% | -34.2% | -19.4% | -16.4% | -34.4% | -23.1% | -63.8% | -54.8% | -23.2% | -15.5% | -30.5% | -30.8% | -18.8% | -12.0% | -8.4% | -7.8% | -6.3% | -7.8% | -16.6% |
| — | -25.8% | -24.7% | -47.7% | +69.6% | +70.1% | -48.5% | -49.2% | -109.1% | -78.2% | -23.2% | -29.7% | -263.4% | -294.7% | -199.1% | -52.5% | +49.4% | +29.9% | +25.6% | +32.0% | +26.6% | |
| ROA | -96.1% | -17.1% | -29.5% | -27.6% | -17.3% | -14.5% | -28.7% | -18.0% | -38.1% | -43.1% | -20.9% | -13.5% | -25.2% | -26.2% | -17.2% | -11.2% | -8.0% | -7.5% | -6.1% | -7.4% | -15.5% |
| — | -18.0% | -2.8% | -53.1% | +54.7% | +66.4% | -37.4% | -33.1% | -51.4% | -64.4% | -21.8% | -20.6% | -214.2% | -248.1% | -182.8% | -52.1% | +48.2% | +28.8% | +25.3% | +32.4% | +22.6% | |
| ROIC | -742.7% | -31.3% | — | — | — | — | -106.0% | -47.4% | — | -182.9% | -28.3% | -22.5% | -64.6% | -908.2% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | -275.1% | -111.3% | — | +79.9% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.88 | 10.01 | 2.75 | 3.88 | 7.34 | 11.74 | 5.22 | 6.76 | 2.06 | 2.82 | 9.45 | 10.45 | 6.30 | 4.88 | 9.65 | 13.06 | 19.45 | 25.67 | 32.17 | 24.19 | 12.45 |
| — | -14.7% | -47.3% | -42.5% | +256.6% | +316.1% | -44.8% | -35.4% | -67.3% | -42.2% | -2.0% | -19.9% | -67.6% | -81.0% | -70.0% | -46.0% | +56.2% | +47.4% | +36.5% | -8.8% | +38.8% | |
| Quick Ratio | 3.88 | 10.01 | 2.75 | 3.88 | 7.34 | 11.74 | 5.22 | 6.76 | 2.06 | 2.82 | 9.45 | 10.45 | 6.30 | 4.88 | 9.65 | 13.06 | 19.45 | 25.67 | 32.17 | 24.19 | 12.45 |
| — | -14.7% | -47.3% | -42.5% | +256.6% | +316.1% | -44.8% | -35.4% | -67.3% | -42.2% | -2.0% | -19.9% | -67.6% | -81.0% | -70.0% | -46.0% | +56.2% | +47.4% | +36.5% | -8.8% | +38.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | -68.59 | — | — | — | -823.17 | — | -201.33 | -48.43 | -79.55 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FBRX stock.
Forte Biosciences, Inc.'s current P/E is -16.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Forte Biosciences, Inc.'s business trajectory between earnings reports.